SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy
Patients with HS on anti-TNF therapy receiving the SARS-CoV-2 mRNA vaccine seroconvert similarly as those without anti-TNF therapy, indicating this population should receive the vaccine and expect a similar degree of protection against COVID-19 compared to HS patients who do not receive anti-TNF therapy.
Authors
- Zahidul Islam (ORCID: https://orcid.org/0009-0001-5522-9668)
- Steven R. Cohen (ORCID: https://orcid.org/0000-0001-7774-1825)
- Peter Ch’en (ORCID: https://orcid.org/0000-0003-0802-0279)
- Kristina L. Campton
- McCall E. Torpey (ORCID: https://orcid.org/0000-0001-7956-9045)
- Avigdor Nosrati (ORCID: https://orcid.org/0000-0002-4200-6801)
- Michelle Toker (ORCID: https://orcid.org/0000-0002-6513-9033)
Institutions
- Albert Einstein College of Medicine (US)
- New York Medical College (US)
- Cornell University (US)
- Keck Hospital of USC (US)
Publication Details
- Journal
- Journal of Cutaneous Medicine and Surgery
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1177/12034754251338809
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00